Comparison of urinary and serum levels of di-22:6-bis(monoacylglycerol)phosphate as noninvasive biomarkers of phospholipidosis in rats

Toxicology Letters

Volumn 213, Issue 2, 2012, Pages 285-291

  Thompson, Karol L ^a   Zhang, Jun ^a   Stewart, Sharron ^a   Rosenzweig, Barry A ^a   Shea, Katherine ^a   Mans, Daniel ^a   Colatsky, Thomas ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Acetaminophen; Bis(monoacylglycerol)phosphate; Phospholipidosis; Phospholipids; Serum biomarkers

Indexed keywords

ALANINE AMINOTRANSFERASE; AMIODARONE; BIOLOGICAL MARKER; DI 22 6 BIS(MONOACYLGLYCEROL)PHOSPHATE; HEXESTROL BIS(2 DIETHYLAMINOETHYL) ETHER; PARACETAMOL; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; HISTOPATHOLOGY; LIPIDOSIS; LIVER HISTOLOGY; LIVER NECROSIS; NONHUMAN; PRIORITY JOURNAL; RAT; URINE LEVEL;

ACETAMINOPHEN; AMIODARONE; ANIMALS; BIOLOGICAL MARKERS; DRUG-INDUCED LIVER INJURY; HISTOCYTOCHEMISTRY; LIPIDOSES; LYSOPHOSPHOLIPIDS; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; PHOSPHOLIPIDS; RATS; RATS, INBRED F344;

RATTUS;

EID: 84864500339     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2012.07.013     Document Type: Article

References (29)

1. Akeda S. A study of the lipidosis induced by a coronary vasodilator, 4,4'-diethylaminoethoxy hexestrol dihydrochloride. Mia Medical Journal 1972, 22:65-96.
2. Atienzar F., Gerets H., Dufrane S., Tilmant K., Cornet M., Dhalluin S., Ruty B., Rose G., Canning M. Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicological Sciences 2007, 96(1):101-114.
3. Baronas E.T., Lee J.W., Alden C., Hsieh F.Y. Biomarkers to monitor drug-induced phospholipidosis. Toxicology and Applied Pharmacology 2007, 218(1):72-78.
4. Chatman L.A., Morton D., Johnson T.O., Anway S.D. A strategy for risk management of drug-induced phospholipidosis. Toxicologic Pathology 2009, 37(7):997-1005.
5. De La Iglesia F., Feuer G., McGuire E.J., Takada A. Morphological and biochemical changes in the liver of various species in experimental phospholipidosis after diethylaminoethoxyhexestrol treatment. Toxicology and Applied Pharmacology 1975, 34:28-44.
6. Delaney J., Neville W.A., Swain A., Miles A., Leonard M.S., Waterfield C.J. Phenylacetylglycine, a putative biomarker of phospholipidosis: its origins and relevance to phospholipid accumulation using amiodarone treated rats as a model. Biomarkers 2004, 9(3):271-290.
7. DeLong E.R., Delong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44(3):837-845.
8. Eng, J., 2006. ROC Analysis: Web-Based Calculator for ROC Curves. Johns Hopkins University, Baltimore. Available from: (updated 17.05.06, cited 06.04.11). http://www.jrocfit.org/.
9. Eskelinen E.L., Tanaka Y., Saftig P. At the acidic edge: emerging functions for lysosomal membrane proteins. Trends in Cell Biology 2003, 13(3):137-145.
10. Gieselmann V. Lysosomal storage diseases. Biochimica et Biophysica Acta 1995, 1270:103-136.
11. Hullin-Matsuda F., Luquain-Costaz C., Bouvier J., Delton-Vandenbroucke I. Bis(monoacylglycero)phosphate, a peculiar phospholipid to control the fate of cholesterol: implications in pathology. Prostaglandins Leukotrienes and Essential Fatty Acids 2009, 81(5-6):313-324.
12. Igusa Y., Yamashina S., Izumi K., Inami Y., Fukada H., Komatsu M., Tanaka K., Ikejima K., Watanabe S. Loss of autophagy promotes murine acetaminophen hepatotoxicity. Journal of Gastroenterology 2011, (Epub ahead of print). 10.1007/s00535-011-0500-0.
13. Jaeschke H., Bajt M.L. Intracellular signaling mechanisms of acetaminophen-induced liver cell death. Toxicological Sciences 2006, 89(1):31-41.
14. Josepovitz C., Levine R., Lane B., Kaloyanides G.J. Contrasting effects of gentamicin and mercuric chloride on urinary excretion of enzymes and phospholipids in the rat. Laboratory Investigation 1985, 52(4):375-386.
15. Kasama K., Yoshida K., Takeda S., Akeda S., Kawai K. Bis-(monoacylglyceryl)phosphate and acyl phosphatidylglycerol isolated from human livers of lipidosis induced by 4,4'-diethylaminoethoxyhexesterol. Lipids 1974, 9:235-243.
16. Kruhlak N.L., Choi S.S., Contrera J.F., Weaver J.L., Willard J.M., Hastings K.L., Sancilio L.F. Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicology Mechanisms and Methods 2008, 18(2-3):217-227.
17. Mazue G., Vic P., Gouy D., Remandet B., Lacheretz F., Berthe J., Barchewitz G., Gagnol J.P. Recovery from amiodarone-induced lipidosis in laboratory animals: a toxicological study. Fundamental and Applied Toxicology 1984, 4:992-999.
18. Meikle P.J., Duplock S., Blacklock D., Whitfield P.D., MacIntosh G., Hopwood J.J., Fuller M. Effect of lysosomal storage on bis(monoacylglycero)phosphate. Biochemical Journal 2008, 411(1):71-78.
19. Mesens N., Desmidt M., Verheyen G.R., Starckx S., Damsch S., Vries R.D., Verhemeldonck M., Gompel J.V., Lampo A., Lammens L. Phospholipidosis in rats treated with amiodarone: serum biochemistry and whole genome micro-array analysis supporting the lipid traffic jam hypothesis and the subsequent rise of the biomarker BMP. Toxicologic Pathology 2012, 40(3):491-503.
20. Mortuza G.B., Neville W.A., Delaney J., Waterfield C.J., Camilleri P. Characterisation of a potential biomarker of phospholipidosis from amiodarone-treated rats. Biochimica et Biophysica Acta 2003, 1631:136-146.
21. Nioi P., Perry B.K., Wang E.J., Gu Y.Z., Snyder R.D. In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Toxicological Sciences 2007, 99(1):162-173.
22. Obert L.A., Sobocinski G.P., Bobrowski W.F., Metz A.L., Rolsma M.D., Altrogge D.M., Dunstan R.W. An immunohistochemical approach to differentiate hepatic lipidosis from hepatic phospholipidosis in rats. Toxicologic Pathology 2007, 35:728-734.
23. Park S., Choi Y.-J., Lee B.-H. In vitro validation of drug-induced phospholipidosis. Journal of Toxicological Sciences 2012, 37:261-267.
24. Pintavorn P., Cook W.J. Progressive renal insufficiency associated with amiodarone-induced phospholipidosis. Kidney International 2008, 74(10):1354-1357.
25. Reasor M.J., Hastings K.L., Ulrich R.G. Drug-induced phospholipidosis: issues and future directions. Expert Opinion on Drug Safety 2006, 5:567-583.
26. Sawada H., Takami K., Asahi S. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicological Sciences 2005, 83(2):282-292.
27. Tengstrand E.A., Miwa G.T., Hsieh F.Y. Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities. Expert Opinion on Drug Metabolism and Toxicology 2010, 6(5):555-570.
28. Thompson K.L., Haskins K., Rosenzweig B.A., Stewart S., Zhang J., Peters D., Knapton A., Rouse R., Mans D., Colatsky T. Comparison of the diagnostic accuracy of di-22:6-bis(monoacylglycerol)phosphate and other urinary phospholipids for drug-induced phospholipidosis or tissue injury in the rat. International Journal of Toxicology 2012, 31(1):14-24.
29. Yamamoto A., Adachi S., Ishikawa K., Yokomura T., Kitani T. Studies on drug-induced lipidosis. 3. Lipid composition of the liver and some other tissues in clinical cases of Niemann-Pick-like syndrome induced by 4,4'-diethylaminoethoxyhexestrol. Journal of Biochemistry 1971, 70(5):775-784.